GGrantIndex
Sort

40,608 grants matching prostate cancer

Erythropoietin Blockade for the Treatment of Cancer

$402,553
C. Anthony Blau · University Of Washington · R01 · FY2012 · CA

Genetic Susceptibility for Prostate Cancer Progression

$402,553
William B Isaacs · Johns Hopkins University · R01 · FY2007 · CA

64-Bit High Performance Computing

$402,523
Edward B Suh · Translational Genomics Research Inst · S10 · FY2007 · RR

Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in Glioblastoma

$402,500
Jennifer S Yu · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · NS

Arginyl-tRNA beyond translation: mechanism and regulation of protein arginylation

$402,500
Yi Zhang · Case Western Reserve University · R35 · FY2024 · GM

Arginyl-tRNA beyond translation: mechanism and regulation of protein arginylation

$402,500
Yi Zhang · Case Western Reserve University · R35 · FY2023 · GM

Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in Glioblastoma

$402,500
Jennifer S Yu · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · NS

Arginyl-tRNA beyond translation: mechanism and regulation of protein arginylation

$402,500
Yi Zhang · Case Western Reserve University · R35 · FY2025 · GM

GENETIC ASSOCIATION STUDY OF ANCESTRY-MATCHED AFRICAN AMERICAN PROSTATE CANCER CASES AND CONTROLS

$402,478
The Johns Hopkins University · · FY2008 · Department of Defense

CHD1 and MAP3K7 coordinate deletion in aggressive ERG translocation negative prostate cancer

$402,456
Scott D Cramer · University Of Colorado Denver · R01 · FY2015 · CA

STAT Activation: Inactivation Cycle and Activated STAT3 in Cancer Cells

$402,453
James E Darnell · Rockefeller University · R01 · FY2008 · AI

STAT Activation: Inactivation Cycle and Activated STAT3 in Cancer Cells

$402,453
James E Darnell · Rockefeller University · R01 · FY2009 · AI

Hypothermic Storage and Cryopreservation of Corneas

$402,445
J M Baust · Cell Preservation Services, Inc. · R44 · FY2009 · EY

Nitric Oxide as a Modifier of Oxidative Stress

$402,444
David Wink · Division Of Clinical Sciences - Nci · ZIA · FY2013 · CA

COMBINING NANOTECHNOLOGY AND RADIATION TO ENHANCE CHECKPOINT BLOCKADE IMMUNOTHERAPY OF ADVANCED PROSTATE CANCER

$402,428
University Of Chicago · · FY2018 · Defense Health Agency

Clinical and Analytical Validation of Cancer Biomarkers

$402,374
Daniel W Chan · Johns Hopkins University · U24 · FY2011 · CA

The structural and functional basis of MET exon 14 activation and acquired drug resistance

$402,355
Natalia Jura · University Of California, San Francisco · R01 · FY2022 · CA

SOUTHWEST ONCOLOGY GROUP--SUMMARY

$402,352
Loyola University Chicago · U10 · FY2003 · CA

Substrate Specificity Determinants in Nutrient Solute Carrier Transporters

$402,346
Avner Schlessinger · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA

Leadership Component in Chemoprevention: Mouse Models of Human Cancer Consortium

$402,325
Cory Abate-Shen · Columbia University Health Sciences · U01 · FY2011 · CA

Tumor Cell Biology Training Program

$402,313
Gay Miriam Crooks · University Of California Los Angeles · T32 · FY2015 · CA

Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies

$402,262
Kris C. Wood · Duke University · R01 · FY2023 · CA

Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer

$402,226
Ian Taylor · Arvinas, Inc. · R44 · FY2017 · CA

Evaluation of Immune-based Combinations in Metastatic Prostate Cancer

$402,223
Ravi Madan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Controlled Release of Macromolecules

$402,150
Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2010 · EB